GelStat launches over-the-counter arthritis reliever

GelStat Arthritis is the company’s second over-the-counter (OTC) product and, like GelStat Migraine, utilizes the company’s patent pending formulation in combination with a sublingual (under the tongue) delivery system.

“Since inception, our research has focused on developing a novel formulation of natural active ingredients that, when combined with advanced delivery systems, offers improved efficacy, safety, and convenience over existing pain relievers. We believed there was a need for such a product, as existing pain relievers often fail to provide sufficient relief and are associated with frequent, serious side effects,” said Dr Stephen Roberts, chairman and CEO of GelStat.

“Recent events have confirmed our initial assessment, as the side effects of many products have increasingly been recognized, with some having been withdrawn from the market entirely. There has never been a greater need for a safe and effective OTC pain reliever,” Roberts continued.

Until recently, Pfizer’s Celebrex and Bextra and Merck & Co’s Vioxx have been the prescription drugs of choice for the treatment of arthritis pain. However, both Vioxx and Bextra have now been withdrawn from the market and Celebrex, along with a number of OTC NSAIDs, will now be required to include warnings on the increased risk of cardiovascular, gastrointestinal and dermatological events associated with their use. As a result, an increasing number of consumers are now in search of alternate pain relief medications.